No Data
No Data
"Unlucky year"! Corning Jerry has yet another critical clinical failure. How much longer until the next product is launched?
①For the overseas key experiment of KN035 in soft tissue sarcoma, the objective response rate of patients can be evaluated as 5%, which is lower than the required 11% for supporting biological product license application; ②With only the commercialization of KN035, several key clinical trials of KN046 have encountered setbacks previously, which further delayed the market launch of the new product by Conagen.
Kn Hospital (02120.HK) saw a 15.2% increase in inpatient bed days in the first half of the year, while daily total spending fell by 7.8%.
KN Hospital (02120.HK) announced that in the second quarter ending in June, there were 955,400 hospital bed days, an increase of 14.1% annually; the total average daily expenditure per bed day for inpatients was 370 yuan RMB, a decrease of 4.9%. The number of outpatient visits was 122,200, a decrease of 3%; the total average expenditure per outpatient visit was 437 yuan, a decrease of 1.8%.
Corning Is Maintained at Hold by Deutsche Bank
Corning Is Maintained at Hold by Deutsche Bank
Corning Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/03/2024 1.59% Deutsche Bank $35 → $39 Maintains Hold 06/21/2024 17.22% Citigroup $38 → $45 Maintains Bu
Deutsche Numis Maintains Corning(GLW.US) With Hold Rating, Raises Target Price to $39
Deutsche Numis analyst Matthew Niknam maintains $Corning(GLW.US)$ with a hold rating, and adjusts the target price from $35 to $39.According to TipRanks data, the analyst has a success rate of 53.9% a
Balancing Growth Prospects With Valuation Concerns: A Hold Rating for Corning